Collegium Pharmaceutical
COLL
70 hedge funds and large institutions have $268M invested in Collegium Pharmaceutical in 2016 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 38 increasing their positions, 8 reducing their positions, and 7 closing their positions.
375% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 8
157% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 7
17% more funds holding
Funds holding: 60 → 70 (+10)
18% less capital invested
Capital invested by funds: $327M → $268M (-$58.3M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$14.5M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$9.19M |
| 3 |
Bank of New York Mellon
New York
|
+$5.65M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$5.35M |
| 5 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$4.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$6.75M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.36M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$1.11M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$358K |
| 5 |
Renaissance Technologies
New York
|
-$328K |
COLL Hedge Fund Activity: Q1 2016 in Review
70 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q1 2016, worth a combined $268M — down 18% from $327M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new COLL positions and 7 closed out — a net gain of 11 holders — while 38 added to existing stakes and 8 trimmed.
The largest buyer was Eventide Asset Management, adding an estimated $14.5M. The largest seller was RA Capital Management, cutting an estimated $6.75M.
- 70 institutional investors held Collegium Pharmaceutical (COLL) as of Q1 2016, up from 60 in Q4 2015.
- Funds reported $268M of Collegium Pharmaceutical stock for Q1 2016, down 18% quarter-over-quarter.
- 18 funds opened new Collegium Pharmaceutical positions in Q1 2016 and 7 closed out, a net change of +11 holders.
- The largest Collegium Pharmaceutical buyer in Q1 2016 was Eventide Asset Management, an estimated $14.5M added.
- The largest Collegium Pharmaceutical seller in Q1 2016 was RA Capital Management, an estimated $6.75M sold.
Based on aggregated 13F filings for Q1 2016.